Espinosa FA, Pereyra FAE, Garibaldi BEM, Sánchez BMD, Arriaga MCI, Ramírez CMA, Alemán SCN, Hernández SDR, Valencia LR

Language: Spanish
References: 26
Page: 12-19
PDF size: 736.01 Kb.

ABSTRACT

Mucormycosis is an infection caused by fungi of the order Mucorales, which occurs particularly in individuals with immunosuppression. The phenotype of the disease is variable, so a high degree of suspicion will favor timely identification and treatment.
The case of a 58-year-old patient with risk factors for mucormycosis who presents febrile syndrome exclusively accompanied by lower respiratory involvement is reported. The initial diagnosis was community pneumonia, however, the patient showed torpid evolution with different antibiotic treatments. Samples were obtained by bronchoscopy, the histological image was compatible with Mucor sp. Directed treatment was started, observing total remission of the clinical manifestations.
A review of the literature related to fungal infections by Mucorales was carried out.

REFERENCES

1. Reid, G., Lynch, J.P. 3rd, Fishbein, M.C. y Clark, N.M.,“Mucormycosis”, Semin Respir Crit Care Med, 2020, 41(1): 99-114.

2. Agrawal, R., Yeldandi, A., Savas, H., Parekh, N.D., Lombardi,P.J. y Hart, E.M., “Pulmonary mucormycosis: riskfactors, radiologic findings, and pathologic correlation”,Radiographics, 2020, 40 (3): 656-666.

3. Jeong, W., Keighley, C., Wolfe, R., Lee, W.L., Slavin,M.A., Kong, D.C.M. y Chen, S.C., “The epidemiologyand clinical manifestations of mucormycosis: a systematicreview and meta-analysis of case reports”, ClinMicrobiol Infect, 2019, 25 (1): 26-34.

4. Bitar, D., Lortholary, O., Le Strat, Y., Nicolau, J., Coignard,B., Tattevin, P., Che, D. y Dromer, F., “Population-basedanalysis of invasive fungal infections, France, 2001-2010”, Emerg Infect Dis, 2014, 20 (7): 1149-1155.

5. Riley, T.T., Muzny, C.A., Swiatlo, E. y Legendre, D.P.,“Breaking the mold: a review of mucormycosis andcurrent pharmacological treatment options”, Ann Pharmacother,2016, 50 (9): 747-757.

6. Ibrahim, A.S., Spellberg, B., Walsh, T.J. y Kontoyiannis,D.P., “Pathogenesis of mucormicosis”, Clin Infect Dis,2012, 54 (suppl_1): s16-s22.

7. Skiada, A., Pagano, L., Groll, A. et al., “Zygomycosis inEurope: analysis of 230 cases accrued by the registryof the European Confederation of Medical Mycology(ecmm) Working Group on Zygomycosis between 2005and 2007”, Clin Microb Infect, 2011, 17 (12): 1859-1867.

8. Muqeetadnan, M., Rahman, A., Amer, S., Nusrat, S.,Hassan, S. y Hashmi, S., “Pulmonary mucormycosis: anemerging infection”, Case Rep Pulmonol, 2012, 2012:120809.

9. Prakash, H. y Chakrabarti, A., “Global epidemiology ofmucormicosis”, J Fungi, 2019, 5 (1): 26.

10. Muthu, V., Agarwal, R., Dhooria, S. et al., “Has the mortalityfrom pulmonary mucormycosis changed overtime? A systematic review and meta-analysis”, Clin MicrobiolInfect, 2021, 27 (4): 538-549.

11. Palanisamy, P.R. y Elango, D., “covid-19 associated mucormycosis:a review”, J Family Med Prim Care, 2022,11 (2): 418-423.

12. Nagalli, S. y Kikkeri, N.S., “Mucormycosis in covid-19: asystematic review of literature”, Infez Med, 2021, 29 (4):504-512.

13. Cornely, O.A., Alastruey-Izquierdo, A., Arenz, D. et al.,“Mucormycosis ecmm msg Global Guideline WritingGroup. Global guideline for the diagnosis and managementof mucormycosis: an initiative of the EuropeanConfederation of Medical Mycology in cooperationwith the Mycoses Study Group Education and ResearchConsortium”, Lancet Infect Dis, 2019, 19 (12):e405-e421.

14. Skiada, A., Lass-Floerl, C., Klimko, N. et al., “Challengesin the diagnosis and treatment of mucormicosis”, MedicalMycology, 2018, 56 (suppl_1): s93–s101.

15. Frater, J.L., Hall, G.S. y Procop, G.W., “Histologic featuresof zygomycosis: emphasis on perineural invasionand fungal morphology”, Arch Pathol Lab Med, 2001,125 (3): 375-378.

16. Walsh, T.J., Gamaletsou, M.N., McGinnis, M.R., Hayden,R.T. y Kontoyiannis, D.P., “Early clinical and laboratorydiagnosis of invasive pulmonary, extrapulmonary, anddisseminated mucormycosis (zygomycosis)”, Clin InfectDis, 2012, 54 Suppl 1: s55-60.

17. Skiada, A., Pavleas, I. y Drogari-Apiranthitou, M., “Epidemiologyand diagnosis of mucormycosis: an update”, JFungi, 2020, 6 (4): 265.

18. Espinel-Ingroff, A. y Turnidge, J., “The role of epidemiologicalcutoff values (ecvs/ecoffs) in antifungal susceptibilitytesting and interpretation for uncommon yeastsand moulds”, Revista Iberoamericana de Micología,2016, 33 (2): 63-75.

19. Chamilos, G., Lewis, R. y Kontoyiannis, D., “Delayingamphotericin b: based frontline therapy significantlyincreases mortality among patients with hematologicmalignancy who have zygomycosis”, Clin Infect Dis,

20. 2008, 47 (4): 503-509.20. Marty, F.M., Ostrosky-Zeichner, L., Cornely, O.A., Mullane,K.M., Perfect, J.R., Thompson, G.R. 3rd et al.,“vital and FungiScope Mucormycosis Investigators. Isavuconazoletreatment for mucormycosis: a single-armopen-label trial and case-control analysis”, Lancet InfectDis, 2016, 16 (7): 828-837.

21. Sipsas, N.V., Gamaletsou, M.N., Anastasopoulou, A. yKontoyiannis, D.P., “Therapy of mucormicosis”, J Fungi,2018, 4 (3): 90.

22. Tissot, F., Agrawal, S., Pagano, L. et al., “ecil-6 guidelinesfor the treatment of invasive candidiasis, aspergillosisand mucormycosis in leukemia and hematopoieticstem cell transplant patients”, Haematologica, 2016,102 (3): 433-444.

23. Afolayan, O., Copeland, H., Zaheer, S. y Wallen, J.M.,“Pulmonary mucormycosis treated with lobectomy”,Ann Thoracic Surg, 2017, 103 (6): e531-e533.

24. Mills, S.E., Yeldandi, A.V. y Odell, D.D., “Surgical treatmentof multifocal pulmonary mucormicosis”, Ann ThorSurg, 2018, 106 (2): e93-e95.

25. Zhao, Y., Prideaux, B., Baistrocchi, S. et al., “Beyondtissue concentrations: antifungal penetration at the siteof infection”, Medical Mycol, 2019, 57 (Supplement_2):s161-s167.

26. Lee, F.Y.W., Mossad, S.B. y Adal, K.A., “Pulmonary mucormicosis”,Archives of Internal Medicine, 1999, 159(12): 1301.